Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial evaluated the safety and efficacy of Moderna's RSV vaccine mRNA-1345 in adults aged 60 and older, spanning Phase 2 and Phase 3, and the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• mRNA-1345

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Respiratory Syncytial Virus | Phase 2, Phase 3 | Status: COMPLETED